SPL

0.00%

10.5¢ starpharma holdings limited

FDA meeting, page-3

First 3 Last

Share
Profile

Follow
thrasher

4,930 Posts.

289

22/03/19

10:12

Post #: 37849099
Share

Originally posted by stockrock: ↑

Hi

The CRL would be more detailed than the two words "confirmatory data", but it won't be so prescriptive as to eliminate all ambiguity.

As such, when responding to a CRL there is always an eliminate of guesswork - albeit an educated and informed guess. Hiring ex-FDA consultants is a given when responding to a CRL, each and every pharma company would take this step. It is prudent and expected of Starpharma to do so.

As such, having these consultants don't give me any extra confidence that they will get a favourable outcome with the FDA in this meeting.

Heard of the song "Ironic"? This line springs to mind ... "It's like having 10,000 spoons, when all you need is a knife".

Doesn't matter how many dollars you spend on advice, if the regulatory body wants a knife and you give them 10,000 different types of spoons .. you will still get knocked back.

Something to keep in mind is that the FDA chooses its words very clearly. If they needed more clinical data, they ask for clinical data in their CRL.

If they want another trial, they ask for confirmatory data.

Starpharma are giving them more clinical data (another spoon).

So all I am saying is that Starpharma are going to be fighting an uphill battle at this next FDA meeting. I am not saying they can't win, I am just pointing out that it won't be easy and the odds are currently against them.

Having partial approval for one indication is not ideal, but possible and better than no approved product this year.. but that is pure speculation on our part as we don't know what is in the CRL. It may sound logical, but there are so many possibilities out there ... how do I justify to myself as an investor to place my hard earned cash based on two words "confirmatory data". Especially when I know what that means.

It's risk awareness and capital protection that I am advocating, and my risk appetite is different to everybody else. However I feel an obligation as part of an investor forum and former shareholder to share this view.

Expand

Always respected your views just don’t completely agree with it this time confirmatory data can come from existing data even fda guidelines say this, could be Starpharma also present a plan to provide new data after some adjusted approval. Lots of possible outcomes I just don’t think worst outcome will be the result.

SPL Price at posting: $1.00 Sentiment: Hold Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 46, 2024

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

First 3 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 10.5¢		Change 0.000(0.00%)		Mkt cap ! $43.90M

Open	High	Low	Value	Volume
10.5¢	11.5¢	10.0¢	$110.6K	1.006M

Buyers (Bids)

No.	Vol.	Price($)
1	83046	10.5¢

Sellers (Offers)

Price($)	Vol.	No.
11.0¢	30000	1

View Market Depth

No.	Vol.	Price($)
1	83046	0.105
3	198569	0.100
1	10111	0.099
3	483557	0.096
1	824859	0.095

Price($)	Vol.	No.
0.110	30000	1
0.115	122753	4
0.120	221197	6
0.125	30000	1
0.130	138570	2

Last trade - 16.10pm 15/11/2024 (20 minute delay)

SPL (ASX) Chart

FDA meeting, page-3

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Banshee's historic trenches prove rich in antimony and gold for GDM

Cyclone signs MOU with Vale for development of Iron Bear play

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

FDA meeting, page-3

Top Stories

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Banshee's historic trenches prove rich in antimony and gold for GDM

Cyclone signs MOU with Vale for development of Iron Bear play

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News